Abstract: The present invention relates to a method for controlling a probe for the treatment of brain tissue using an assembly comprising the probe and an acoustic window (1), the probe (2) including a plurality of transducers (21) for generating ultrasound waves, the method comprising: —a phase of detection: •of the probe transducers situated above the cranium (4) of the patient, and •of the probe transducers situated above the acoustic window (1), so as to permit: •deactivation of the transducers situated above the cranium (4) of the patient, •activation of the transducers situated above the acoustic window (1).

Abstract: The disclosure provides methods and compositions useful for labeling of target molecules with origin-specific nucleic acid identifiers (for example, barcodes), which can be used subsequently to identify, quantify, or otherwise characterize a feature or activity of target molecules originating from a particular discreet volume. Such target molecules can include polypeptides expressed by cells, in which nucleic acid molecules encoding the polypeptides are labeled with the same, or matched, origin-specific nucleic acid identifiers.

Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.

Abstract: A device for forcibly inserting a surgical implant into a receiving bone (4), by impaction, comprising an impactor (10) which exerts an impact force on the implant and is associated with at least one sensor (12). The sensor (12) measures the deformation of the impactor (10), and provides a measurement signal representing the temporal variation of the deformation during an impact. The sensor (12) is connected to a processing unit (30) configured to calculate, on the basis of the temporal variation of the deformation of the impactor (10) during the impact, an indicator representative of the level of contact between the implant and the receiving bone (4).

Abstract: A device for assessing the solidity of a material comprising an ancillary tool (2) having an end (2B) in the form of a point or blade, an impactor (4) for striking the ancillary tool (2), a sensor (12) and a processing unit (30). The ancillary tool (2) is placed between a material (8) and the impactor (4) and transmits the impact force generated by the impactor (4) to the material (8). The sensor (12) is capable of measuring a quantity from among the impact force and the deformation of the impactor, and of supplying a measurement signal. The processing unit (30) is suitable for calculating, from the measurement signal, an indicator representative of the solidity of the material (8). The indicator corresponds to the duration of a time window between the first peak (P1) of maximum amplitude of the measurement signal and the second peak of maximum amplitude (P2).

Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.

Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.

Abstract: Compositions resulting from the mixing of at least one copolymer A1, resulting from the copolymerization of at least one monomer functionalized by diol functions with at least one styrenic monomer, and at least one compound A2 comprising at least two boronic ester functions. They have very varied rheological properties depending on the proportion of compounds A1 and A2 used. Composition resulting from the mixing of at least one lubricating oil with such a composition of associative and exchangeable polymers and use of this composition for lubricating a mechanical part.

Abstract: Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia.

Abstract: A method for performing spacetime-constrained oblivious transfer between various laboratories of a first party A and various laboratories of a second party B. The method includes providing the spacetime-constrained oblivious transfer to satisfy various conditions. The method further includes encoding, by the laboratories of the first party A, various messages in a quantum state selected from various non-orthogonal quantum states. The method further includes transmitting, by the laboratories of the first party A, the quantum state to a first laboratory of the second party B. The method further includes applying, by the first laboratory of the second party B, a quantum measurement on the quantum state to obtain a classical measurement outcome. The method further includes transmitting, by the first laboratory of the second party B, the classical measurement outcome to the laboratories of the second party B.

Abstract: The present invention relates to a surgical kit for use in a craniectomy procedure, the surgical kit comprising: a medical device to be implanted in a cranial bone of a patient, the medical device (10) including several transducers for emitting ultrasound waves for treatment of brain tissue, a surgical accessory (20) intended to be positioned on the cranial bone of the patient, the surgical accessory (20) including a body whose outer perimeter defines the dimensions of an opening that is to be made in the cranial bone of the patient in order to receive the medical device, characterized in that the surgical accessory (20) comprises a plurality of holes (201) formed in the body, the position of each hole (201) on the body coinciding with the position of the axis of symmetry of a respective transducer, such that the accessory is able to be positioned optimally through the joint use of a neuronavigation system.

Abstract: The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.

Abstract: A method for depositing an object, including: —approaching, in an enclosure, a holder in the direction of a carrier substrate, then—transferring, in the enclosure, the object from the holder to an area for depositing the carrier substrate. The transfer step is preferably carried out when the inside of the enclosure is in a vacuum at a pressure below 10?6 bar.

Abstract: Compositions resulting from the mixing of at least: a comb polydiol copolymer A1 and a compound A2 including at least two boronic ester functional groups, the comb polydiol copolymer A1 including a main chain and side chains, at least a portion of the side chains of the copolymer A1 being composed of oligomers. They exhibit very varied rheological properties depending on the proportion of the compounds A1 and A2 used. Composition resulting from the mixing of at least one lubricating oil with such a composition of associative and exchangeable polymers and use of this composition for lubricating a mechanical part.

Abstract: A sensor for the continuous in-situ analysis of an aerosol flow for measuring the mass of the micron/submicron particles suspended in the air flow, including an aeraulic sorter allowing the particles to be sorted according to their size with an impactor body with a cascade of one or more stages; at least one MEMS microbalance per stage, with an oscillating silicon membrane located on the impaction zone of the particles; processor connected to each MEMS microbalance to determine the mass of all the particles on the impaction zone; a system for cleaning the MEMS microbalances allowing the evacuation of the particles from the MEMS microbalances; means for driving the aerosol flow.

Abstract: The present invention relates to an ambient backscattering communication system (14), the communication system (14) comprising: an ambient backscattering transmitter (16) suitable for generating an ambient backscattering signal according to a first polarization from an ambient signal incident on the transmitter (16), an ambient backscattering receiver (18) suitable for detecting the ambient backscattering signal transmitted by the ambient backscattering transmitter according to a second polarization, and a reduction device (22) for reducing the interference between the ambient backscattering signal and an ambient signal incident on the receiver, the reduction device (22) controlling the first polarization and the second polarization and wherein at least one of said first and second polarizations is adjustable.

Abstract: An antagonist antibody, or an antigen binding fragment thereof, binds both to human and macaque LILRB1 and/or LILRB2, and has diagnostic and therapeutic uses.

Abstract: A spectroscopy device including: an electron source arranged to emit a flux of electrons towards a sample, a pulsed photon source emitting photon pulses towards the sample, at least one spectrometer for receiving a flux of electrons originating from the sample, at least one electron detector; and at least one deflector, between the electron source and the at least one electron detector, synchronized with the pulsed photon source to allow or prevent the passage of electrons emitted by the electron source, towards the electron detector.

Abstract: The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.

Abstract: A nickel-based superalloy includes, in atomic percentages, 13% to 21% chromium, 15% to 26% cobalt, 4% to 8% aluminum, 4.5% to 8% titanium, 8% to 18% iron, boron in an atomic percentage less than or equal to 0.5% or no boron, carbon in an atomic percentage less than or equal to 1% or no carbon, at least one additional element selected from molybdenum, tungsten, tantalum and niobium, a total atomic content of the at least one additional element being less than or equal to 1.5% or no such at least one additional element, the remainder being nickel and unavoidable impurities, with a sum of the atomic percentages of aluminum and titanium being comprised between 8.5% and 15%. The novel superalloy composition has a limited density and exhibiting, when hot, good mechanical properties as well as good resistance to oxidation and corrosion.